Action 600200 JIANGSU WUZHONG PHARMACEUTICAL DEVELOPMENT CO., LTD.
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Autres langues JiangSu WuZhong Pharmaceutical Development Co., Ltd.

Actions

600200

CNE000000YP4

Cours en clôture Shanghai S.E.
Autres places de cotation
 00:00:00 29/04/2024 		Varia. 5j. Varia. 1 janv.
10,95 CNY +3,79 % Graphique intraday de JiangSu WuZhong Pharmaceutical Development Co., Ltd. -1,35 % +33,21 %
24/04 JiangSu WuZhong Pharmaceutical Development Co. présente ses résultats pour le premier trimestre clos le 31 mars 2024 CI
24/04 JiangSu WuZhong Pharmaceutical Development Co. publie ses résultats pour l'exercice clos le 31 décembre 2023 CI

Autres langues

Recherche
Voir les résultats
Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !
Inscription 100% Gratuite
JiangSu WuZhong Pharmaceutical Development Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024
JiangSu WuZhong Pharmaceutical Development Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023
JiangSu WuZhong Pharmaceutical Development Co., Ltd. cancelled the transaction announced on April 25, 2023
JiangSu WuZhong Pharmaceutical Development Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023
Jiangsu WuZhong Pharma to Invest 30 Million Yuan in Local Biotech Firm
Wuzhong Pharmaceutical Development's Unit Gets Registration Certificate for Linezolid Sodium Chloride Injection
JiangSu WuZhong Pharmaceutical Development Co., Ltd.(XSSC:600200) added to S&P Global BMI Index
JiangSu WuZhong Pharmaceutical Development Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023
JiangSu WuZhong Pharmaceutical Development Co., Ltd. cancelled the transaction announced on November 11, 2021
JiangSu WuZhong Pharmaceutical Development Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022
JiangSu WuZhong Pharmaceutical Development Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023
JiangSu WuZhong Pharmaceutical Development Co., Ltd. announced that it expects to receive CNY 1.2 billion in funding from Zhejiang Fuji Holdings Group Co., Ltd. and other investors
Cinkate Medicine Chemical Intermediate Co., Ltd. agreed to acquire 15% stake in Suzhou Changzheng Cinkate Pharmaceutical Co., Ltd. from JiangSu WuZhong Pharmaceutical Development Co., Ltd. for CNY 33 million.
JiangSu WuZhong Pharmaceutical Development Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022
JiangSu WuZhong Pharmaceutical Development Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022
JiangSu WuZhong Pharmaceutical Development Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022
JiangSu WuZhong Pharmaceutical Development Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021
JiangSu WuZhong Pharmaceutical Development Co., Ltd. cancelled the transaction to acquire 70% stake in Shanghai Weina Cosmetics Co., Ltd., from Weina Hongkong Co., Limited.
Jiangsu Wuzhong Pharmaceutical Group Corporation announced that it expects to receive CNY 340 million in funding from JiangSu WuZhong Pharmaceutical Development Co., Ltd.
JiangSu WuZhong Pharmaceutical Development Co., Ltd. announced that it expects to receive CNY 300 million in funding from Suzhou Fuji Suwu Pharmaceutical Technology Partnership Enterprise (Limited Partnership)
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action 600200
  4. Actualités JiangSu WuZhong Pharmaceutical Development Co., Ltd.
  5. Autres langues